Sangamo Therapeutics, Inc. (SGMO) Financial Ratios
27 years of historical data (1999–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
30Y Low13.5·High172.4
P/B Ratio
↑
N/A
—
5yr avg: 3.68
30Y Low1.1·High9.0
ROE
↓
-2891.8%
↑-337% vs avg
5yr avg: -662.4%
30Y Low-185%·High-16%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SGMO Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Sangamo Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $75M | $118M | $206M | $95M | $485M | $1.1B | $2.1B | $938M | $1.1B | $1.3B | $215M |
| Enterprise Value | $80M | $124M | $194M | $88M | $427M | $953M | $2.0B | $902M | $1.0B | $1.3B | $197M |
| P/E Ratio → | -0.41 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.89 | 2.98 | 3.56 | 0.54 | 4.35 | 9.79 | 17.75 | 9.16 | 13.18 | 35.02 | 11.10 |
| P/B Ratio | — | — | 9.04 | 1.14 | 1.64 | 2.89 | 4.22 | 2.17 | 3.03 | 6.82 | 1.58 |
| P/FCF | — | — | — | — | — | — | 13.52 | — | — | 172.40 | — |
| P/OCF | — | — | — | — | — | — | 12.35 | — | 29.95 | 114.55 | — |
P/E links to full P/E history page with 30-year chart
SGMO EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.12 | 3.36 | 0.50 | 3.84 | 8.61 | 17.00 | 8.81 | 11.84 | 34.33 | 10.16 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | 12.95 | — | — | 169.02 | — |
SGMO Profitability
Margins and return-on-capital ratios measuring operating efficiency
Sangamo Therapeutics, Inc. earns an operating margin of -273.1%. Operating margins have compressed from -155.5% to -273.1% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -2891.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 80.8% | 80.8% | 100.0% | 100.0% | 89.1% | 100.0% | -52.8% | -42.5% | -36.0% | -79.7% | -238.4% |
| Operating Margin | -273.1% | -273.1% | -179.9% | -155.5% | -180.8% | -165.6% | -109.6% | -102.7% | -91.4% | -154.1% | -374.2% |
| Net Profit Margin | -310.8% | -310.8% | -169.4% | -146.3% | -172.8% | -161.1% | -102.4% | -92.9% | -80.9% | -149.2% | -369.6% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -2891.8% | -2891.8% | -185.4% | -136.5% | -57.4% | -40.9% | -26.0% | -23.8% | -24.6% | -33.7% | -43.6% |
| ROA | -152.4% | -152.4% | -73.4% | -70.8% | -29.9% | -21.5% | -15.4% | -15.5% | -15.6% | -24.5% | -38.2% |
| ROIC | -5405.6% | -5405.6% | -178.8% | -131.1% | -62.6% | -42.1% | -24.1% | -24.2% | -27.7% | -30.1% | -45.2% |
| ROCE | -295.5% | -295.5% | -119.9% | -96.4% | -38.5% | -26.4% | -19.0% | -19.5% | -20.5% | -29.2% | -42.5% |
SGMO Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $6M ($27M total debt minus $21M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 1.34 | 0.46 | 0.15 | 0.13 | 0.08 | 0.10 | 0.08 | 0.13 | 0.03 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -0.50 | -0.09 | -0.19 | -0.35 | -0.18 | -0.08 | -0.31 | -0.13 | -0.13 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | -0.58 | — | — | -3.38 | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
SGMO Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.84x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 1.98x to 0.84x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.84 | 0.84 | 1.13 | 1.98 | 2.69 | 3.12 | 4.60 | 5.80 | 5.23 | 5.54 | 11.25 |
| Quick Ratio | 0.84 | 0.84 | 1.13 | 1.98 | 2.69 | 3.12 | 4.60 | 5.80 | 5.23 | 5.57 | 11.27 |
| Cash Ratio | 0.49 | 0.49 | 0.92 | 1.70 | 2.49 | 2.94 | 4.47 | 5.19 | 5.10 | 5.42 | 10.72 |
| Asset Turnover | — | 0.66 | 0.57 | 1.07 | 0.20 | 0.15 | 0.13 | 0.16 | 0.14 | 0.13 | 0.12 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 97.02 | 29.04 | 8.42 | 14.67 | 20.98 | 19.33 | 133.95 | 21.82 | 35.76 | 97.82 |
SGMO Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Sangamo Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | 7.4% | — | — | 0.6% | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $280M | $202M | $174M | $154M | $145M | $134M | $112M | $97M | $78M | $71M |
Peer Comparison
Compare SGMO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SGMOYou | $75M | -0.4 | — | — | 80.8% | -273.1% | -2891.8% | -5405.6% | — |
 EDIT | $263M | -1.5 | — | — | 100.0% | -245.2% | -198.1% | — | — |
 CRSP | $5B | -8.4 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 BEAM | $4B | -42.1 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 NTLA | $2B | -4.1 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 PRME | $583M | -2.4 | — | — | -58.1% | -4498.1% | -146.8% | -168.3% | — |
 FATE | $244M | -1.8 | — | — | -94.1% | -2222.4% | -51.8% | -36.5% | — |
 RCKT | $366M | -1.7 | — | — | — | — | -60.3% | -62.4% | — |
 ILMN | $25B | 29.7 | 22.7 | 26.4 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 TMO | $173B | 26.2 | 18.7 | 27.4 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 PACB | $435M | -0.8 | — | — | 31.7% | -348.5% | -213.5% | -45.8% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 27 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
SGMO — Frequently Asked Questions
Quick answers to the most common questions about buying SGMO stock.
What is Sangamo Therapeutics, Inc.'s P/E ratio?
Sangamo Therapeutics, Inc.'s current P/E ratio is -0.4x. This places it at the 50th percentile of its historical range.
What is Sangamo Therapeutics, Inc.'s ROE?
Sangamo Therapeutics, Inc.'s return on equity (ROE) is -2891.8%. The historical average is -44.1%.
Is SGMO stock overvalued?
Based on historical data, Sangamo Therapeutics, Inc. is trading at a P/E of -0.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Sangamo Therapeutics, Inc.'s profit margins?
Sangamo Therapeutics, Inc. has 80.8% gross margin and -273.1% operating margin.